

Mumps Virus, Enders

Catalog No. NR-3846

This reagent is the property of the U.S. Government.

Lot (NIAID Catalog) No. V-325-001-000

For research use only. Not for human use.

Contributor:

National Institutes of Allergy and Infectious Diseases (NIAID),
National Institutes of Health

Product Description:

Reagent: Seed Virus

Virus Classification: *Paramyxoviridae, Rubulavirus*

Agent: Mumps virus

Strain/Isolate: Enders

NIAID Class: Research Reference Reagent

Source: ATCC #VR-106

Donor Passage History (# of passages):

Rhesus monkey kidney (unknown)

Chicken embryo (amnion) (17)

Chicken embryo (allantoic) (35)

Producer Passage History (# of passages):

Chicken embryo (allantoic) (10)

Material Provided/Storage:

Composition: 90% allantoic fluid and 10% sucrose gelatin

Volume: 1.0 mL

Storage Temperature: -60°C or colder

Functional Activity:

Infectivity:

Conditions: Rhesus monkey kidney

TCID₅₀: 1 X 10⁵ – 1.6 X 10⁶ per mL

Conditions: Human amnion

TCID₅₀: 5 X 10⁴ per mL

Conditions: 8-day chicken embryo (allantoic)

TCID₅₀: 3.2 X 10⁷ per mL

Complement Fixation:

Conditions: 2 units of activated complement (C'); 2 hours
at 37°C

Titer: 1:51

Hemagglutination:

Conditions: Chicken red blood cells; 1 hour at room
temperature

Titer: 1:640

Date of Last Test: June, 1969

Note: BEI Resources was asked to distribute this virus preparation from NIAID's historical repository. Recent characterization information is not yet available.

Purity:

Serum Neutralization Breakthrough: Negative

Bacterial Sterility: Negative

Mycoplasma: Negative

Producer and Contract:

Chas. Pfizer and Company, Inc., PH-43-62-842

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Mumps Virus, Enders, NR-3846."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmb15/bmb15toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. The Tissue Culture Infectious Dose 50% (TCID₅₀) endpoint is the 50% infectious endpoint in tissue culture. The TCID₅₀ is the dilution of virus that under the

conditions of the assay can be expected to infect 50% of the cultures inoculated, just as a Lethal Dose 50% (LD₅₀) is expected to kill half of the animals exposed. A reciprocal of the dilution required to yield the TCID₅₀ provides a measure of the titer (or infectivity) of a virus preparation.

2. Enders, J. F., et al. "Immunity in Mumps: I. Experiments with Monkeys (*Macacus mulatta*). The Development of Complement-Fixing Antibody Following Infection and Experiments on Immunization by Means of Inactivated Virus and Convalescent Human Serum." J. Exp. Med. 81 (1945): 93–117.
3. Enders, J. F., et al. "Immunity in Mumps: II. The Development of Complement-Fixing Antibody and Dermal Hypersensitivity in Human Beings Following Mumps." J. Exp. Med. 81 (1945): 119–135.
4. Enders, J. F., et al. "Immunity in Mumps: III. The Complement Fixation Test as an Aid in the Diagnosis of Mumps Meningoencephalitis." J. Exp. Med. 81 (1945): 137–150.
5. Levens, J. H. and J. F. Enders. "The Hemoagglutinative Properties of Amniotic Fluid from Embryonated Eggs infected with Mumps Virus." Science 102 (1945): 117–120. PubMed: 17777358.
6. Cabasso, V. J. "Contributions of Tissue Culture to Canine Hepatitis and Distemper Vaccination." J. Am. Vet. Med. Assoc. 136 (1960): 1–8. PubMed: 13806669.

ATCC® is a trademark of the American Type Culture Collection.